Rocket


Overview
Financials
News + Filings
Key Docs
Ownership


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

I-Mab (IMAB) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503"
08/17/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates · Significant progress made year-to-date on key clinical assets: - Uliledlimab : Encouraging early results were presented at ASCO 2023 - Givastomig : Topline Phase 1 data with promising early efficacy signals, including patients with low levels of Claudin 18.2 tumor expression. Data to be presented at ESMO 2023 · Eftansomatropin alfa : Phase 3 pivotal study evaluating weekly injection of eftansomatropin alfa met the primary endpoint of annualized height velocity at week 52 and demonstrated non-inferiority to Norditropin®, administered by daily injection. A BLA filing is being planned for 2024 · Strong cash position of RMB3.0 billion as of June 30, 2023, to support execution of the Company’ s..."
05/26/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC Receiving Uliledlimab and Toripalimab Combination Therapy at ASCO 2023"
05/01/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2022 · Strategic reprioritization of the Company’ s pipeline to focus on key clinical assets and overall streamlining of corporate structure and workforce, resulting in a significant reduction in the cash burn rate and in significant pipeline achievements by focus · Thirteen key clinical milestones achieved in 2022, including positive data readout for lemzoparlimab, uliledlimab, and givastomig and significant progress on eftansomatropin alfa and felzartamab. Phase 3 data readout of eftansomatropin alfa and potential biologics license applications submission expected by the end of 2023 or early 2024 · I-Mab and AbbVie continue to collaborate on the global developm..."
05/01/2023 6-K Quarterly results
04/25/2023 6-K Quarterly results
04/25/2023 6-K Quarterly results
04/03/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K"
03/31/2023 6-K Quarterly results
11/10/2022 6-K Quarterly results
09/30/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K"
09/13/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"I-Mab Announces Positive Phase 2 Data of Lemzoparlimab in Combination with Azacitidine in Patients with Higher Risk Myelodysplastic Syndrome at ESMO 2022",
"I-Mab Announces Approval from China CDE to Initiate Phase 3 Registrational Study of Lemzoparlimab in Combination with Azacitidine in Higher-Risk Myelodysplastic Syndrome GAITHERSBURG, MD. and SHANGHAI, China – September 13, 2022 – I-Mab , a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it has successfully completed an End-of-Phase 2 meeting with the Center for Drug Evaluation of China’ s National Medical Products Administration , and has obtained approval from the CDE to initiate a Phase 3 registrational trial evaluating lemzoparlimab, a novel CD47 antibody, in combination with azacitidine for the first-line treatment of patients with newly diagnosed higher-risk myelodysplastic syndrome . The..."
08/30/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K"
08/16/2022 6-K Quarterly results
05/27/2022 6-K Quarterly results
05/18/2022 6-K Quarterly results
05/05/2022 6-K Quarterly results
04/28/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"I-Mab Announces Appointments of Richard Yeh as Chief Operating Officer and John Hayslip as Chief Medical Officer"
03/31/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"I-Mab Announces Voluntary Lock-ups by Key Shareholders and Senior Management for Long-Term Commitment"
03/29/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2021"
03/04/2022 6-K Quarterly results
02/22/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K"
01/28/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"I-Mab's Announcement on Unusual Price Movement SHANGHAI, China, and GAITHERSBURG, MD. - I-Mab , a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics. The Company has noted the recent unusual fluctuations in the price and trading volume of the American depositary shares of the Company and emphasizes that its business and pipeline developments are all well on track and have no adverse changes. The Company has strong confidence in its global competitive pipeline and is accelerating ongoing transformation towards an integrated global biopharma as planned. Latest Development of Lemzoparlimab and Uliledlimab:"
12/21/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"I-Mab Strengthens Management Team Designed to Accelerate Global Pipeline Development and Transformation Towards Commercialization"
12/15/2021 6-K Quarterly results
12/10/2021 6-K Quarterly results
12/08/2021 6-K Quarterly results
12/06/2021 6-K Quarterly results
11/12/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"— Unaudited Condensed Consolidated Interim Financial Statements",
"— Discussion of Unaudited Financial Statements",
"— Updated Risk Factors"
11/12/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"I-Mab and ABL Bio Report Preclinical Data of 4-1BB-targeting Bispecific Antibodies at 2021 SITC",
"I-Mab and Jumpcan Announce Strategic Commercial Partnership on Eftansomatropin Alfa"
11/05/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"—",
"—"
11/02/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"I-Mab Strengthens Senior Executive Team with New Chief Financial Officer and Chief Strategy Officer Appointments"
10/19/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"I-Mab Announces IND Approval for Phase 2 Clinical Trial of Efineptakin Alfa in Combination with PD-1 Therapy in China SHANGHAI, China and GAITHERSBURG, MD. October 18, 2021 - I-Mab , a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Center for Drug Evaluation of the China National Medical Products Administration has approved the IND submission for the initiation of phase 2 clinical trial of efineptakin alfa in combination with PD-1 antibody in patients with advanced solid tumors, including triple-negative breast cancer as well as head and neck cancers. Efineptakin alfa is the world's first and only long-acting recombinant human interleukin-7 developed as a T lymphocyte-booster for cancer-re..."
10/15/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"I-Mab Advances Late-stage Development of Its Differentiated CD38 Antibody Felzartamab in China"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy